Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mixture of Adipose-derived Cells Prove Better at Inducing Bone Repair

By LabMedica International staff writers
Posted on 06 Mar 2019
Researchers have defined the differential but overlapping roles of two cell subsets involved in the paracrine induction of bone repair.

Paracrine signaling is a form of cell-to-cell communication in which a cell produces a signal to induce changes in nearby cells, altering the behavior of those cells. More...
Signaling molecules known as paracrine factors diffuse over a relatively short distance, as opposed to endocrine factors, hormones, which travel considerably longer distances via the circulatory system.

Pericytes are multi-functional cells that wrap around the endothelial cells that line the capillaries and venules throughout the body. These cells are embedded in basement membrane where they communicate with endothelial cells of the capillaries by means of both direct physical contact and paracrine signaling. Pericytes and other perivascular stem/stromal cells are of growing interest in the field of tissue engineering. A fraction of perivascular cells are well recognized to have mesenchymal stem cell (MSC) characteristics, including multipotentiality, self-renewal, immunoregulatory functions, and diverse roles in tissue repair.

Investigators at Johns Hopkins University (Baltimore, MD, USA) evaluated the differential but overlapping roles of two perivascular cell subsets in paracrine induction of bone repair. CD146+CD34−CD31−CD45−pericytes and CD34+CD146−CD31−CD45−adventitial cells were derived from human adipose (fat) tissue and applied alone or in a 1:1 combination to treat severe defects in the skulls of mice.

Results published in the January 7, 2019, online edition of the journal NPJ Regenerative Medicine revealed that pericytes induced growth of new blood vessels, while adventicytes induced the formation of bone synthesizing osteoblasts. For this study, the investigators performed in vitro osteogenic differentiation and tubulogenesis assays using either fluorescence activated cell sorting-derived CD146+ pericytes or CD34+ adventitial cells. The results indicated that the two types of cells working in tandem were better at promoting bone repair in mice than was either type by itself.

“Given these distinct but overlapping roles in bone repair, future use of a combination progenitor cell therapy may be effective,” said senior author Dr. Aaron James, associate professor of pathology at Johns Hopkins University. “Although our study used equal numbers of each type of cell, it will be important to study whether different ratios of these two cell types can support even more dramatic bone repair.”

“A prevailing theory in stem cell therapies derived from fat is that a heterogeneous cell population somehow works in concert to speed tissue regeneration, like different instruments in an orchestra playing in unison,” said Dr. James. “But the cellular or molecular mechanisms behind this theory have not been defined. The current study tried to isolate specific subpopulations of cells to try to determine which would work best. This study shows that two different cell populations - pericytes and adventicytes - can be used to regenerate tissue in a sort of beneficial duet, with distinct but complementary roles.”

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Immunoassay Analyzer
SuperFlex™
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.